| pubmed-article:10411568 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0014139 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0034792 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0599756 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0684180 | lld:lifeskim |
| pubmed-article:10411568 | lifeskim:mentions | umls-concept:C0333668 | lld:lifeskim |
| pubmed-article:10411568 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10411568 | pubmed:dateCreated | 1999-8-18 | lld:pubmed |
| pubmed-article:10411568 | pubmed:abstractText | Recent evidence supporting a role for phosphoinositides in the endocytosis of phospholipase C-coupled receptors has prompted an investigation of whether there exists a similar requirement for the internalization of adenylyl cyclase-linked receptors. When 1321N1 astrocytoma cells, which possess both muscarinic cholinergic receptors (mAChRs) that couple to phospholipase C and beta-adrenergic receptors (beta(2)-ARs) linked to adenylyl cyclase, were pretreated with wortmannin (WT) at a concentration known to inhibit phosphatidylinositol 4-kinase activity, the labeling of both phosphatidylinositol 4-phosphate and phosphatidylinositol 4, 5-bisphosphate (PIP(2)) was reduced. Stimulation of phosphoinositide breakdown by activation of mAChRs in WT-pretreated cells led to a further depletion of PIP(2). As previously demonstrated for SH-SY5Y neuroblastoma, inclusion of WT inhibited the endocytosis of mAChRs in 1321N1 cells by >85%. In contrast, the internalization of beta(2)-ARs was only partially ( approximately 30%) prevented. However, when the concentration of PIP(2) was further reduced by exposure of WT-pretreated 1321N1 cells to a muscarinic agonist, the endocytosis of beta(2)-ARs was substantially inhibited (>70%). Lower concentrations of WT (100 nM) that were sufficient to fully inhibit phosphatidylinositol 3-kinase activity had no effect on either phosphoinositide synthesis or receptor endocytosis. The results indicate that the agonist-induced endocytosis of an adenylyl cyclase-linked receptor such as the beta(2)-AR, like that of the phospholipase C-coupled mAChR, is dependent on the synthesis of phosphoinositides and, in particular, that of PIP(2). | lld:pubmed |
| pubmed-article:10411568 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10411568 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411568 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10411568 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10411568 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:10411568 | pubmed:author | pubmed-author:FisherS KSK | lld:pubmed |
| pubmed-article:10411568 | pubmed:author | pubmed-author:HeacockA MAM | lld:pubmed |
| pubmed-article:10411568 | pubmed:author | pubmed-author:McEwenE LEL | lld:pubmed |
| pubmed-article:10411568 | pubmed:author | pubmed-author:LinsemanD ADA | lld:pubmed |
| pubmed-article:10411568 | pubmed:author | pubmed-author:SorensenS DSD | lld:pubmed |
| pubmed-article:10411568 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10411568 | pubmed:volume | 290 | lld:pubmed |
| pubmed-article:10411568 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10411568 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10411568 | pubmed:pagination | 603-10 | lld:pubmed |
| pubmed-article:10411568 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:meshHeading | pubmed-meshheading:10411568... | lld:pubmed |
| pubmed-article:10411568 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10411568 | pubmed:articleTitle | Inhibition of beta(2)-adrenergic and muscarinic cholinergic receptor endocytosis after depletion of phosphatidylinositol bisphosphate. | lld:pubmed |
| pubmed-article:10411568 | pubmed:affiliation | Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA. | lld:pubmed |
| pubmed-article:10411568 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10411568 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:10411568 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10411568 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10411568 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10411568 | lld:pubmed |
